This expanded access study is designed to provide RAD001 to patients with MRCC who are without satisfactory treatment alternatives, until RAD001 becomes commercially available.

Inclusion criteria:

• ≥ 18 years old; metastatic renal cancer, intolerant of or failed sunitinib and/or sorafenib
• Adequate bone marrow function, liver function, renal function
• Adequate birth control

Exclusion criteria:

• Previously received RAD001 or other mTOR inhibitors, known hypersensitivity to rapamycin, chronic systemic treatment with corticosteroids or immunosuppressive agents (prednisone ≤ 20 mg/day for adrenal insufficiency OK
• Topical or inhaled steroids OK)
• Active bleeding
• Uncontrolled angina, CHF, heart attack ≤ 6 months, uncontrolled diabetes

Other protocol-defined inclusion/exclusion criteria may apply